VYNE THERAPEUTICS INC (VYNE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$39.50+8.46%
Close 2026-08-24 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · VYNE
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The Company has initiated dosing in a Phase 2a/2b trial evaluating YB-101 in patients with GD, with or without concurrent TED, and the molecule has received Fast Track Designation from the U.S. Food…
Stated in 1 of 1 supplied quarters. Management reported: “The Company has initiated dosing in a Phase 2a/2b trial evaluating YB-101 in patients with GD, with or without concurrent TED, and the molecule has received Fast Track Designation from the U.S. Food and Drug Administration (“FDA”).” “Data from the Phase 2a portion of the trial are expected in the second half of 2027.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“3 Yarrow Bioscience is seeking to bring life into balance for patients suffering with Graves’ Disease and TED 4 Yarrow expects to have the first anti - TSHR to enter Phase 2 in GD ; supported by indu…”
Yarrow’s cash balance is expected to support the Company’s operations into 2028.
Stated in 1 of 1 supplied quarters. Management reported: “Yarrow’s cash balance is expected to support the Company’s operations into 2028.” “Frey, PharmD, President and CEO, Yarrow Mona Ashiya, PhD, General Partner at OrbiMed Steve Hoerter, Chairman and Chief Executive Officer at MBX Biosciences Peter Silverman, JD, Former Chief Operating Officer and General Counsel at Merus Bill White, Chief Financial Officer & Head of Corporate Development at Avere Transaction Financial Information As previously announced, Yarrow successfully completed pre-closing private placements that resulted in total gross proceeds of approximately $200 million.”
“3 Yarrow Bioscience is seeking to bring life into balance for patients suffering with Graves’ Disease and TED 4 Yarrow expects to have the first anti - TSHR to enter Phase 2 in GD ; supported by indu…”
The combined company will operate as Yarrow Bioscience, Inc., with its shares expected to begin trading on the Nasdaq Capital Market on Tuesday, July 28, 2026, under the ticker symbol “YARW.”
Stated in a supplied disclosure. Management reported: “The combined company will operate as Yarrow Bioscience, Inc., with its shares expected to begin trading on the Nasdaq Capital Market on Tuesday, July 28, 2026, under the ticker symbol “YARW.””
Progress clinical trials of YB-101, a first-in-class anti-TSHR antibody, including Phase 2a/2b trials and data readouts in Graves' Disease and thyroid eye disease.
Manage cash and cost structure to ensure sufficient funding for operations into the first half of 2027.
Over the trailing year it converted 1.16x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
14 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.